Cargando…

Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report

INTRODUCTION: Teneligliptin, an antidiabetic agent classified as a class III dipeptidyl peptidase-4 (DPP-4) inhibitor, has a unique structural feature that provides strong binding to DPP-4 enzymes. We investigated the efficacy and safety of switching patients with type 2 diabetes mellitus (T2DM) who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hae Jin, Kim, Young Sik, Lee, Chang Beom, Choi, Moon-Gi, Chang, Hyuk-Jae, Kim, Soo Kyoung, Yu, Jae Myung, Kim, Tae Ho, Lee, Ji Hyun, Ahn, Kyu Jeung, Kim, Kyoungmin, Lee, Kwan Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612358/ https://www.ncbi.nlm.nih.gov/pubmed/31079357 http://dx.doi.org/10.1007/s13300-019-0628-0

Ejemplares similares

Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study
por: Kim, Hae Jin, et al.
Publicado: (2021)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2020)

Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase‐4 inhibitors
por: Nakamaru, Yoshinobu, et al.
Publicado: (2016)

Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor
por: Takahara, Yusuke, et al.
Publicado: (2018)

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
por: Lee, Jung Min, et al.
Publicado: (2019)

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Reduces Aortic Damage from Hypercholesterolaemia in Apolipoprotein E-Deficient Mice
por: Zhang, Ying, et al.
Publicado: (2017)

Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial
por: Kim, M. K., et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis
por: Lee, Sahmin, et al.
Publicado: (2020)

Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation
por: Lee, Choon-Soo, et al.
Publicado: (2016)

Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
por: Ha, Kyoung Hwa, et al.
Publicado: (2018)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

The dipeptidyl peptidase‐4 (DPP‐4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice
por: Takeda, Kenichiro, et al.
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study
por: Kim, Young-Gun, et al.
Publicado: (2018)

Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database
por: Suh, Sunghwan, et al.
Publicado: (2015)

Dipeptidyl Peptidase 10, a Novel Prognostic Marker in Colorectal Cancer
por: Park, Heae Surng, et al.
Publicado: (2013)

Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients
por: Park, Hyo Eun, et al.
Publicado: (2015)

Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes
por: Ito, Rika, et al.
Publicado: (2015)

Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus
por: Inn, Kyung-Soo, et al.
Publicado: (2018)

Constituents of Coreopsis lanceolata Flower and Their Dipeptidyl Peptidase IV Inhibitory Effects
por: Kim, Bo-Ram, et al.
Publicado: (2020)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase‐4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24‐week multicentre, randomized, double‐blind, placebo‐controlled phase III trial
por: Hong, S., et al.
Publicado: (2016)

Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
por: Oh, Tae Jung, et al.
Publicado: (2013)

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
por: Ideta, Takayasu, et al.
Publicado: (2015)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double‐blind, non‐inferiority trial
por: Kim, Yonghyun, et al.
Publicado: (2018)

Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice
por: Ban, Tae H, et al.
Publicado: (2019)

Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis
por: Park, Se Hee, et al.
Publicado: (2016)

A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis
por: Homma, Koichiro, et al.
Publicado: (2017)

The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory
por: Pujadas, Gemma, et al.
Publicado: (2016)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)

Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
por: Jung, Gwon-Soo, et al.
Publicado: (2016)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study
por: Kim, Young-Gun, et al.
Publicado: (2018)

Response: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52)
por: Suh, Sunghwan, et al.
Publicado: (2015)

Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus
por: Shimoda, Masashi, et al.
Publicado: (2017)

Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
por: Jang, Yun-Mi, et al.
Publicado: (2011)

SAT-173 Antiproliferative Effect of Teneligliptin on Atherosclerosis in Vascular Smooth Muscle Cell
por: Moon, Shinje, et al.
Publicado: (2019)

Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Kim, Mi-Jin, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
por: Kim, Kyoung Jin, et al.
Publicado: (2019)

Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees
por: Lee, Ji Yeon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vajvggiu2qiun86m5g3dmpsf8t